Project description DEENESFRITPL AHR: pro or con cancer? The aryl hydrocarbon receptor (AHR) is a transcription factor that controls key biological processes and becomes activated by the binding of a ligand. Its role in antitumour immunity seems to be context dependent, demonstrating both promoting and suppressive effects. This questions its suitability as an anticancer drug target and necessitates further investigation into its mechanism of action. Funded by the European Research Council, the CancAHR project will investigate the downstream effects of AHR activation and delineate its implication in cancer. Results will have clinical projections as they may be used to stratify cancer patients and design specific therapeutic interventions. Show the project objective Hide the project objective Objective The aryl hydrocarbon receptor (AHR) is a critical regulator of tumor progression by modulating both tumor cell intrinsic malignant properties as well as anti-tumor immunity. However, depending on the context, the AHR can exert either tumor-promoting or tumor-suppressive effects, thus limiting its potential as a drug target. To exploit the AHR for cancer therapy a comprehensive understanding of its activation and biological outcomes is necessary. The opposing effects of the AHR in cancer likely stem from the complexity of its activation and biological functions, which are cell type-, ligand-, and context-specific. Moreover, recent results from our laboratory suggest that nutritional stress conditions also affect AHR activity. The detection of AHR activation in tissues mainly relies on the quantitation of AHR target gene expression. However, until recently, the context specificity of AHR target gene expression had impeded systematic investigation of AHR activity across human cancers. Our team has developed a pan-tissue AHR signature that detects AHR activity irrespective of cell type or ligand, and enables the analysis of the biological functions mediated through AHR activation. The combination of the AHR signature with iterative cycles of computational biology analyses and laboratory experimentation puts us in a unique position to investigate AHR activation and its downstream effects. CancAHR will hence systematically delineate how the AHR is activated in cancer, why AHR activation is cell type-specific, and which AHR downstream mediators drive clinical outcomes. The identification of the molecular mechanisms underlying the diverse outcomes of AHR activation in cancer will enable (i) the identification of patients, in which AHR activation contributes to clinical outcome; (ii) the development of clinical interventions tailored to the specific mechanisms of AHR activation; and (iii) stratification of patients to precision therapies modulating AHR activity. Fields of science natural scienceschemical sciencesorganic chemistryhydrocarbonsmedical and health sciencesclinical medicineoncology Programme(s) HORIZON.1.1 - European Research Council (ERC) Main Programme Topic(s) ERC-2021-COG - ERC CONSOLIDATOR GRANTS Call for proposal ERC-2021-COG See other projects for this call Funding Scheme HORIZON-AG - HORIZON Action Grant Budget-Based Coordinator DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG Net EU contribution € 1 999 925,00 Address Im neuenheimer feld 280 69120 Heidelberg Germany See on map Region Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
